Evidence suggests dyslipidemia may appear and persist in the early stages of AD, interacting with pathological proteins like Aβ and p‐tau to initiate pathogenesis that mediate neuroinflammation, oxidative stress, and affect the vascular microenvironment and blood–brain barrier (BBB) integrity, ultimately leading to brain atrophy, and cognitive impairment [1, 2]. This evidence concerns the gene MAPT and Alzheimer disease.